- Conditions
- Carcinoma
- Interventions
- Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 401
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- RMC-5552
- Drug
- Lead sponsor
- Nicholas Butowski
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Non-clear Cell Renal Cell Carcinoma
- Interventions
- Everolimus, Sunitinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 5 more
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
- Interventions
- Nab-Rapamycin, Nivolumab
- Drug · Biological
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Kidney Cancer
- Interventions
- Everolimus, Sunitinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Houston, Texas • Salt Lake City, Utah
- Conditions
- Gout Chronic, Hyperuricemia
- Interventions
- SEL-212, SEL-037, SVP-rapamycin (SEL-110)
- Drug
- Lead sponsor
- Selecta Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 13
- States / cities
- Anaheim, California • El Cajon, California • Irvine, California + 10 more
- Conditions
- Organ Transplantation
- Interventions
- Belatacept, Sirolimus, Alemtuzumab
- Drug
- Lead sponsor
- Allan D Kirk, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Drug
- Lead sponsor
- Robert Nickel
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Hematologic Neoplasms
- Interventions
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI)
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease, Graft Versus Host Disease
- Interventions
- Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil
- Drug · Procedure
- Lead sponsor
- Monica Bhatia
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Autoimmune Diseases
- Interventions
- Efalizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Head And Neck Cancer
- Interventions
- Erlotinib, RAD001
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polycystic Kidney Diseases
- Interventions
- Rapamune
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Transplantation
- Interventions
- Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
- Conditions
- Liver Transplant
- Interventions
- arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
- Biological · Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Interventions
- AL58805, AL3818, Temozolomide (TMZ), CCNU
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
- Interventions
- AG-01 Compound
- Drug
- Lead sponsor
- A&G Pharmaceutical Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Avastin, RAD001
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Lapatinib and RAD-001
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Renal Cell Carcinoma
- Interventions
- Erlotinib hydrochloride, Sirolimus
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cancer, Leukemia, Lymphoma
- Interventions
- Sirolimus and Methotrexate
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
- Drug · Other
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 92 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Anemia
- Interventions
- PBSC Transplant, Alemtuzumab, Sirolimus, Cyclophosphamide, Low Dose Irradiation
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland